{"id":220997,"date":"2017-06-19T23:50:28","date_gmt":"2017-06-20T03:50:28","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/cerescan-demos-ceremetrix-at-society-for-nuclear-medicine-business-wire-press-release.php"},"modified":"2017-06-19T23:50:28","modified_gmt":"2017-06-20T03:50:28","slug":"cerescan-demos-ceremetrix-at-society-for-nuclear-medicine-business-wire-press-release","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/cerescan-demos-ceremetrix-at-society-for-nuclear-medicine-business-wire-press-release.php","title":{"rendered":"CereScan Demos CereMetrix at Society for Nuclear Medicine &#8230; &#8211; Business Wire (press release)"},"content":{"rendered":"<p><p>    DENVER--(BUSINESS    WIRE)--CereScan, a leading    provider of neuro-diagnostics solutions, presented the newest    features, capabilities and use cases of its    CereMetrix platform during the Society for Nuclear    Medicine and Molecular Imaging (SNMMI) Annual Conference at the    Colorado Convention Center last week. CereMetrix is a patented,    statistically-correlated, normative and scalable medical    database designed to aid in the diagnosis and treatment of the    human brain.  <\/p>\n<p>    CereMetrix will provide the healthcare community with the most    robust resource on conditions like traumatic brain injury,    toxic brain injury, Alzheimers Disease and other dementias,    PTSD, bipolar disorder, ADHD, anxiety, autism and depression.    Its a brain focused medical analytics platform that may    accelerate the accurate and effective diagnosis of complex    brain-related disorders to improve treatment and outcomes for    patients.  <\/p>\n<p>    We see SNMMI members as core stakeholders for CereMetrix and    wanted to engage them to both share our vision and get feedback    on the solution. Im happy to report that the response was    overwhelmingly favorable and we now feel that we are innovating    in the right direction, said John Kelley Jr., Chairman and CEO    of CereScan.  <\/p>\n<p>    The key attributes of CereMetrix include:  <\/p>\n<p>    About CereScan  <\/p>\n<p>    CereScan combines state-of-the-art brain imaging    technologies with a patient-centered model of care to provide    the highest level of neuro-diagnostics available. CereScan    utilizes state-of-the-art gamma camera technology, new    generation imaging software and a proprietary process to    produce comprehensive medical reports including voxel level    images of brain function and physiology. Our functional brain    imaging technologies are the most sophisticated in the world    today. Additional information about the company is available at    <a href=\"https:\/\/cerescan.com\" rel=\"nofollow\">https:\/\/cerescan.com<\/a>.  <\/p>\n<p>    CereScan and CereMetrix are registered    trademark of CereHealth Corp.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read the original post: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.businesswire.com\/news\/home\/20170619005950\/en\/CereScan\u00ae-Demos-CereMetrix\u00ae-Society-Nuclear-Medicine-Molecular\" title=\"CereScan Demos CereMetrix at Society for Nuclear Medicine ... - Business Wire (press release)\">CereScan Demos CereMetrix at Society for Nuclear Medicine ... - Business Wire (press release)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> DENVER--(BUSINESS WIRE)--CereScan, a leading provider of neuro-diagnostics solutions, presented the newest features, capabilities and use cases of its CereMetrix platform during the Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Conference at the Colorado Convention Center last week. CereMetrix is a patented, statistically-correlated, normative and scalable medical database designed to aid in the diagnosis and treatment of the human brain <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/cerescan-demos-ceremetrix-at-society-for-nuclear-medicine-business-wire-press-release.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[26],"tags":[],"class_list":["post-220997","post","type-post","status-publish","format-standard","hentry","category-molecular-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/220997"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=220997"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/220997\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=220997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=220997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=220997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}